QCM Cayman’s Akebia Therapeutics AKBA Stock Holding History

QCM Cayman’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-12,059	Closed	-$41K	–	119
2021 Q1	$41K	Buy	+12,059	New	+$43.4K	0.12%	103

Other funds holding AKBA

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

QCM Cayman's AKBA Position: Q2 2021 in Review

QCM Cayman sold out of Akebia Therapeutics (AKBA) in Q2 2021, closing a stake of 12,059 shares — an estimated $41K sold.

QCM Cayman first reported a position in AKBA in Q1 2021 and held it in 1 quarter. The position peaked at $41K in Q1 2021. 139 funds tracked by Wall St. Rank hold AKBA as of Q2 2021.

QCM Cayman reported no remaining Akebia Therapeutics position as of Q2 2021 after selling out during the quarter.
QCM Cayman sold 12,059 Akebia Therapeutics shares in Q2 2021, an estimated $41K.
QCM Cayman first reported a position in Akebia Therapeutics in Q1 2021 and held it in 1 quarter.
QCM Cayman's Akebia Therapeutics position peaked at $41K in Q1 2021.
139 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2021.

Based on QCM Cayman's 13F filing for Q2 2021, filed 10 Aug 2021.